| Literature DB >> 28532497 |
Liang-Bin Xiong1, Hao-Hao Liu1, Li-Qin Xu1, Wan-Ju Sun1, Feng-Qing Wang2, Dong-Zhi Wei3.
Abstract
BACKGROUND: The strategy of modifying the sterol catabolism pathway in mycobacteria has been adopted to produce steroidal pharmaceutical intermediates, such as 22-hydroxy-23,24-bisnorchol-4-ene-3-one (4-HBC), which is used to synthesize various steroids in the industry. However, the productivity is not desirable due to some inherent problems, including the unsatisfactory uptake rate and the low metabolic efficiency of sterols. The compact cell envelope of mycobacteria is a main barrier for the uptake of sterols. In this study, a combined strategy of improving the cell envelope permeability as well as the intracellular sterol metabolism efficiency was investigated to increase the productivity of 4-HBC.Entities:
Keywords: 22-Hydroxy-23,24-bisnorchol-4-ene-3-one (4-HBC); Mycobacterium; Sterol catabolism; choM; cyp125; fadA5; mmpL3
Mesh:
Substances:
Year: 2017 PMID: 28532497 PMCID: PMC5440992 DOI: 10.1186/s12934-017-0705-x
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Localization of the mmpL3 homologues in the genome of M. neoaurum ATCC 25795 and other mycobacteria. The size and direction of genes from the predicted genome information were displayed as an arrow according to the scale. The percentages, such as 94 and 72%, indicate the sequence identity of mmpL3 from M. neoaurum ATCC 25795 with the homologs in M. neoaurum NRRL B-3805, M. neoaurum VKM Ac-1815D, and M. tuberculosis H37Rv
Fig. 2Effects of deleting mmpL3 on cell permeability and the cholesterol utilization. a Evidence for allelic replacement at the mmpL3 locus of M. neoaurum ATCC 25795. The wild-type (WT) 4839-bp sequence was replaced by a 2145-bp fragment ligated with a 1074-bp upstream sequence and a 1071-bp downstream of the mmpL3 (m) gene, thus resulting in the mmpL3-deficient M. neoaurum (m-mut1 and m-mut2). MWM molecular weight marker. b Effects of MmpL3 disruption on cell permeability. Diluted cell suspensions were stained with fluorescein diacetate (FDA) and then the mixtures were detected by a fluorescence spectrophotometer. c Growth characteristics of the wild-type M. neoaurum ATCC 25795 (WT, squares), the deficiency strain of mmpL3 in the WT (ΔmmpL3, open circles) and the complementation strain of mmpL3 in the ΔmmpL3 (ΔmmpL3+mmpL3, triangles) cultured in MM with 1.0 g/L cholesterol. The control is the medium containing 1.0 g/L cholesterol without inoculum. d Quantitative determination of residual cholesterol from the three strains cultured in MM with 1.0 g/L cholesterol. Data represent mean ± standard deviation of three measurements
Fig. 3Schematic profiles of the conversion pathway of sterol to 4-HBC. Sterols share a common and conserved degradation pathway. Here, the cholesterol was used as the model substrate of the sterol catabolism pathway. The disruptions of several enzymes to block the sterol catabolism pathway, resulting in the accumulation of 4-HBC, was colored with green font. The genes colored with red font in the upstream conversion pathway of sterol to 4-HBC were individually overexpressed in the strain WIIIΔmmpL3
Fig. 4Effects of deleting mmpL3 on the improvement in 4-HBC production in the engineered mycobacterial strains. a Improvement in cell permeability in the mmpL3-deleted strain. The engineered strains were stained with FDA, incubated at 32 °C for 10 min and then the mixtures were analyzed by the fluorescence spectrophotometer. b Growth of the previously constructed 4-HBC-producing strain (WIII) and the mmpL3-deleted strain WIIIΔmmpL3 in MYC/02 medium with 2.0 g/L phytosterol. CFU colony forming unit. c Quantitative analyses of the 4-HBC production of the aerobic bioconversion by 4-HBC-producing strains in MYC/02 medium with 2.0 g/L phytosterol. Data represent the mean ± standard deviation of three measurements
Fig. 5Enhancement of the 4-HBC productivity by overexpressing the genes in the sterol conversion pathway. a Assessment of the 4-HBC production for overexpressing the genes in the upstream conversion pathway of sterol to 4-HBC. b Growth of the WIIIΔmmpL3-cyp125-choM1-fadA5 (co-overexpression of cyp125, choM1, and fadA5 in the strain WIIIΔmmpL3) and its ancestral strain WIII in MYC/02 medium with 2.0 g/L phytosterol. c Assessment of the 4-HBC production in the constructed 4-HBC-producing strains. A “cyclodextrin-resting cell” system with 20 g/L of phytosterol was used to determine the productivity of the engineered strains. Data represent the mean ± standard deviation of three measurements
Strains and plasmids used in this study
| Name | Description | Source |
|---|---|---|
| Strains | ||
| | Type strain of | ATCC |
| Δ |
| This study |
| Δ |
| This study |
| WIII |
| [ |
| WIIIΔ |
| This study |
| WIIIΔ |
| This study |
| Plasmids | ||
| p2NIL | Vector of two homologous arms for allelic recombination in mycobacteria, | [ |
| p2N- | p2NIL carrying two homologous arms of | This study |
| pGOAL19 |
| [ |
| p19- | p2NIL-derived with selection cassette from pGOAL19 for deletion of | This study |
| pMV261 | Shuttle vector of | Dr. W. R. Jacobs Jr. |
| p261- | Recombinant pMV261, for overexpression of ChoM1 in mycobacteria | This study |
| p261- | Recombinant pMV261, for overexpression of ChoM2 in mycobacteria | This study |
| p261- | Recombinant pMV261, for overexpression of CYP125 in mycobacteria | This study |
| p261- | Recombinant pMV261, for overexpression of FadA5 in mycobacteria | This study |
| p261- | Recombinant pMV261, for overexpression of CYP125, ChoM1, and FadA5 in mycobacteria | This study |
| pMV306 | Integration vector in | Dr. W. R. Jacobs Jr. |
| p306- | pMV306-P | This study |